

Charles Khouri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428328/publications.pdf>

Version: 2024-02-01

44
papers

808
citations

623699

14
h-index

580810

25
g-index

49
all docs

49
docs citations

49
times ranked

925
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Facial Paralysis With mRNA COVID-19 Vaccines. <i>JAMA Internal Medicine</i> , 2021, 181, 1243.	5.1	88
2	SGLT2 inhibitors and the risk of lower-limb amputation: Is this a class effect?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1531-1534.	4.4	75
3	The French health pass holds lessons for mandatory COVID-19 vaccination. <i>Nature Medicine</i> , 2022, 28, 232-235.	30.7	73
4	Drug-induced Raynaud's phenomenon: beyond β -adrenoceptor blockers. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 6-16.	2.4	55
5	Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 512-523.	8.7	47
6	Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. <i>Journal of Clinical Epidemiology</i> , 2021, 134, 14-21.	5.0	42
7	Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: An effect size meta-analysis. <i>Wound Repair and Regeneration</i> , 2017, 25, 883-891.	3.0	37
8	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. <i>European Respiratory Journal</i> , 2019, 53, 1802472.	6.7	37
9	On-Demand Sildenafil as a Treatment for Raynaud Phenomenon. <i>Annals of Internal Medicine</i> , 2018, 169, 694.	3.9	26
10	Intermittent hypoxia-related alterations in vascular structure and function: a systematic review and meta-analysis of rodent data. <i>European Respiratory Journal</i> , 2022, 59, 2100866.	6.7	21
11	Peripheral vasoconstriction induced by β -adrenoceptor blockers: a systematic review and a network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 549-560.	2.4	19
12	Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. <i>Annals of Internal Medicine</i> , 2021, 174, 878-880.	3.9	19
13	Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances. <i>Frontiers in Pharmacology</i> , 2021, 12, 668765.	3.5	19
14	High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 73-79.	5.0	19
15	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. <i>Chest</i> , 2018, 154, 136-147.	0.8	18
16	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e237-e246.	3.9	18
17	Cardiac consequences of intermittent hypoxia: a matter of dose? A systematic review and meta-analysis in rodents. <i>European Respiratory Review</i> , 2022, 31, 210269.	7.1	18
18	A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 191-198.	5.0	16

#	ARTICLE	IF	CITATIONS
19	Adenovirus <scp>COVIDâ€™19</scp> Vaccines and Guillainâ€™BarrÃ© Syndrome with Facial Paralysis. Annals of Neurology, 2022, 91, 162-163.	5.3	15
20	Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. Journal of Clinical Medicine, 2021, 10, 2089.	2.4	14
21	Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, e103-e105.	1.5	12
22	Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitorâ€™induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2406-2408.e1.	3.8	10
23	Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. British Journal of Clinical Pharmacology, 2020, 86, 2217-2222.	2.4	9
24	Impact of the â€™French Levothyrox crisisâ€™ on signal detection in the World Health Organization pharmacovigilance database. Pharmacoepidemiology and Drug Safety, 2018, 27, 1427-1428.	1.9	8
25	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	3.2	8
26	Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action. British Journal of Clinical Pharmacology, 2022, 88, 3535-3536.	2.4	8
27	Fluoxetine and Raynaud's phenomenon: friend or foe?. British Journal of Clinical Pharmacology, 2017, 83, 2307-2309.	2.4	7
28	Safety Profile of Sclerosing Agents. Dermatologic Surgery, 2019, 45, 1517-1528.	0.8	7
29	Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. British Journal of Clinical Pharmacology, 2022, 88, 5227-5237.	2.4	7
30	French translation and linguistic validation of the Raynaud's condition score. Therapie, 2019, 74, 627-631.	1.0	6
31	Adverse event reporting and Bell's palsy risk after COVID-19 vaccination. Lancet Infectious Diseases, The, 2021, 21, 1490-1491.	9.1	6
32	Severe central sleep apnoea associated with nalmefene: a case report. British Journal of Clinical Pharmacology, 2018, 84, 1075-1076.	2.4	5
33	Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database. Journal of the American Academy of Dermatology, 2021, 85, 229-232.	1.2	5
34	Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. European Respiratory Journal, 2021, 58, 2101576.	6.7	5
35	Skin necrosis and calcifications after extravasation of vancomycin: a localised form of calciphylaxis?. Journal of Wound Care, 2021, 30, 390-393.	1.2	4
36	Implantable cardiac devices in sleep apnoea diagnosis: A systematic review and meta-analysis. International Journal of Cardiology, 2022, 348, 76-82.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Proton pump inhibitors and Raynaud's phenomenon: is there a link?. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2443-2444.	2.4	2
38	Impact of Bariatric Surgery on Medication Efficacy: an Analysis of World Health Organization Pharmacovigilance Data. <i>Obesity Surgery</i> , 2021, 31, 2823-2830.	2.1	1
39	Gout and Levodopa: An unknown adverse effect?. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 221-223.	1.9	1
40	Caution in Interpreting Facial Paralysis Data to Understand COVID-19 Vaccination Risks—Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1420-1421.	5.1	1
41	Impact of global warming on Raynaud's phenomenon: a modelling study. <i>F1000Research</i> , 2020, 9, 829.	1.6	1
42	Pharmacology and pharmacovigilance of protein kinase inhibitors. <i>Therapie</i> , 2021, , .	1.0	1
43	Triptans and SCAD. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2129-2130.	2.8	1
44	Treatment efficacy in secondary Raynaud's phenomenon — Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e132-e133.	3.9	0